Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· longevityutaAudio language not provided

Rentosertib and proteomic aging clocks in idiopathic pulmonary fibrosis: an exploratory substudy

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

At a glance

Automatic summary · not editorially reviewed

The description presents a small exploratory proteomic substudy of a phase 2a trial in people with idiopathic pulmonary fibrosis, examining how treatment with the experimental drug Rentosertib related to proteomic aging clocks. The creator stresses this is not proof that Rentosertib reverses human aging. [1]

  1. The discussed data come from a small exploratory proteomic substudy of a clinical phase 2a trial in people with idiopathic pulmonary fibrosis. [1]

  2. Proteomic aging clocks attempt to estimate biological age or age-related changes from certain protein patterns in the blood. [1]

  3. The creator states the results are not proof that Rentosertib reverses aging in humans. [1]

Rentosertib tested in idiopathic pulmonary fibrosis

According to the description, Rentosertib is an experimental drug currently being studied, among other things, in idiopathic pulmonary fibrosis. The data discussed come from a small exploratory proteomic substudy of a clinical phase 2a trial. The creator notes that the results do not mean Rentosertib has been shown to 'rejuvenate' people. [1]

What proteomic aging clocks aim to estimate

The description explains that proteomic aging clocks try to estimate biological age or age-related changes from certain protein patterns in the blood. It also distinguishes biological age from the age on an identity card. The video is said to cover what these clocks measure and what was actually observed in the phase 2a study. [1]

Creator urges caution with anti-aging headlines

The creator says the findings are exciting but do not show that Rentosertib rejuvenates humans, and calls for close scrutiny of spectacular anti-aging headlines. The description states the data are no proof that Rentosertib reverses aging in humans. It also notes the drug is experimental and the results are no recommendation for use. [1]

Context & limits

This is based only on the video description; the video and transcript were not reviewed. The description gives no sample size, follow-up, comparator details or numerical results, and the substudy is described as small and exploratory.

Based on the creator’s description; the full video and transcript were not analyzed.

[1] Kann ein Medikament das biologische Alter zurückdrehen? Neue Studie überrascht
Quoted passages in the original language
kleinen explorativen Proteom-Substudie einer klinischen Phase-2a-Studie
anhand bestimmter Proteinmuster im Blut biologisches Alter
kein Nachweis dafür, dass Rentosertib das Altern

About this video

Creator description · original textText language: German

Kann ein Medikament unser biologisches Alter beeinflussen? Eine neue Studie in *Nature Biotechnology* sorgt für Aufmerksamkeit: Forschende haben bei Menschen mit idiopathischer Lungenfibrose untersucht, wie sich die Behandlung mit dem experimentellen Wirkstoff Rentosertib auf verschiedene proteomische Aging Clocks auswirkt. Diese „Alterungsuhren“ versuchen, anhand bestimmter Proteinmuster im Blut biologisches Alter beziehungsweise altersbezogene Veränderungen abzuschätzen. Die Ergebnisse sind spannend – aber sie bedeuten nicht, dass Rentosertib Menschen nachweislich „verjüngt“. In diesem Video erkläre ich: • was Rentosertib überhaupt ist • was proteomische Aging Clocks messen • was in der Phase-2a-Studie tatsächlich beobachtet wurde • warum biologisches Alter nicht dasselbe ist wie das Alter im Personalausweis • und weshalb wir bei spektakulären Anti-Aging-Schlagzeilen genau hinschauen müssen Rentosertib wird derzeit als experimenteller Wirkstoff unter anderem bei idiopathischer Lungenfibrose untersucht. Die hier besprochenen Daten stammen aus einer kleinen explorativen Proteom-Substudie einer klinischen Phase-2a-Studie und sind kein Nachweis dafür, dass Rentosertib das Altern beim Menschen umkehrt. 🔬 Wissenschaftliche Quellen: Zhavoronkov A. et al. Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nature Biotechnology. 2026. doi: 10.1038/s41587-026-03286-y Nature Biotechnology: https://www.nature.com/articles/s41587-026-03286-y Rentosertib Phase-2a-Studie: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine. 2025. doi: 10.1038/s41591-025-03743-2 https://www.nature.com/articles/s41591-025-03743-2 Hinweis: Dieses Video dient ausschließlich der allgemeinen Information und wissenschaftlichen Einordnung. Es ersetzt keine individuelle medizinische Beratung. Rentosertib ist ein experimenteller Wirkstoff; aus den dargestellten Forschungsergebnissen ergibt sich keine Empfehlung zur Anwendung. Ich bin Uta Hardt, Apothekerin mit über 20 Jahren Berufserfahrung. Auf diesem Kanal ordne ich aktuelle Forschung zu Healthy Aging, Medikamenten, Nahrungsergänzung und Longevity verständlich und kritisch ein. #Longevity #BiologischesAlter #HealthyAging #Rentosertib #AgingResearch

longevityuta · 9 min · Source published: 2026-10-11

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…